Wang Wei, Zheng Hao
Graduate School of Bengbu Medical College, Bengbu, China.
Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital, Hangzhou, China.
Front Cardiovasc Med. 2021 Mar 5;8:631817. doi: 10.3389/fcvm.2021.631817. eCollection 2021.
Cardiovascular diseases have been regarded as the leading cause of death around the world, with myocardial infarction (MI) being the most severe form. MI leads to myocardial apoptosis, cardiomyocyte fibrosis, and cardiomyocyte hypertrophy, ultimately leading to heart failure, and death. Micro RNAs (miRNAs) participate in the genesis and progression of myocardial pathology after MI by playing an important regulatory role. This review aims to summarize all available knowledge on the role of miRNAs in the myocardial pathological process after MI to uncover potential major target pathways. In addition, the main therapeutic methods and their latest progress are also reviewed. miRNAs can regulate the main signaling pathways as well as pathological processes. Thus, they have the potential to induce therapeutic effects. Hence, the combination of miRNAs with recently developed exosome nanocomplexes may represent the future direction of therapeutics.
心血管疾病被认为是全球主要的死亡原因,其中心肌梗死(MI)是最严重的形式。心肌梗死会导致心肌细胞凋亡、心肌纤维化和心肌细胞肥大,最终导致心力衰竭和死亡。微小RNA(miRNAs)通过发挥重要的调节作用参与心肌梗死后心肌病理的发生和发展。本综述旨在总结关于miRNAs在心肌梗死后心肌病理过程中作用的所有现有知识,以揭示潜在的主要靶标途径。此外,还综述了主要的治疗方法及其最新进展。miRNAs可以调节主要信号通路以及病理过程。因此,它们具有诱导治疗效果的潜力。因此,miRNAs与最近开发的外泌体纳米复合物的结合可能代表治疗的未来方向。